window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : January 21, 2026

  • News
  • About Us
Contact Us

Phase 1 clinical trial

  • Biotech,Cell & Gene Therapy,Clinical Development,Clinical Trials,Opthalmology,Rare Diseases,Research & Development

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    January 16, 2026
  • Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Precision medicine,Research & Development

    FoRx Therapeutics starts first-in-human trial of novel PARG inhibitor FORX-428 in advanced solid tumors

    FoRx Therapeutics has initiated a first-in-human clinical trial of FORX-428, [...]

    August 11, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B
    Categories: Biotech, Cell & Gene Therapy, Clinical Development, Clinical Trials, Opthalmology, Rare Diseases, Research & Development
  • Tjoapack expands oral solid dose bottle packaging capacity at Netherlands facility
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Pharmaceuticals and therapeutics, Supply Chain & Logistics
  • Vetter advances launch preparations for V-OVS next tamper-evident syringe closure system
    Categories: Biomanufacturing, CDMOs & Manufacturing, Drug Delivery & Formulation, Facilities and infrastructure, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top